ArticleDiscover oncology2025
Synergistic bioinformatics and sophisticated machine learning unveil ferroptosis-driven regulatory pathways and immunotherapy potential in breast carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reactive Oxygen Species in Breast Cancer: From Redox Dysregulation to ROS-Responsive Therapeutics.Cell biochemistry and function · 2026Review
- METTL16 antagonizes astaxanthin-induced ferroptosis in colorectal cancer cells.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe intersection of aberrant iron metabolism and the rapidly advancing field of immunotherapy has emerged as a critical focus in breast cancer (BRCA) therapeutics. Ferroptosis, a distinct form of iron-dependent cell death driven by lipid peroxidation, has garnered increasing attention for its pivotal role in cancer progression.
methodsUtilizing extensive datasets from TCGA and GEO, this research extracted a wealth of biological data, including mRNA splicing indices, genomic aberrations, copy number variations (CNV), tumor mutational burden (TMB), and diverse clinical information. Through precise Lasso regression analysis, this research constructed a prognostic model that elucidates the molecular interactions of FRGs in BRCA. Concurrent co-expression network analyses were performed to explore the dynamic interplay between gene expression patterns and FRGs, revealing potential regulatory mechanisms.
resultsThis research analysis revealed significant overexpression of FRGs in high-risk BRCA samples, highlighting their prognostic relevance beyond traditional clinical parameters. GSVA identified immune response and cancer-related pathways as predominantly active in high-risk groups, suggesting ferroptosis as a central modulator within the tumor microenvironment. Notably, genes such as ACTL8, VGF, and CPLX2 emerged as markers of tumorigenesis, while IL33 and TP63 were identified as potential key regulators of cancer progression, each exhibiting distinct expression profiles across risk levels. Furthermore, this research incorporated gene correlations, CNV profiles, SNP arrays, and drug susceptibility analyses, contributing to the advancement of precision oncology.
conclusionsThe integration of bioinformatics and machine learning in this study underscores a strong correlation between FRG expression patterns and BRCA prognosis, affirming their potential as precise biomarkers for personalized immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.